What's new

Certificates Processing System: Demo & Q&A session for Industry stakeholders (H+V), Online, from 27 March 2025, 12:30 (CET) to 27 March 2025, 13:00 (CET)

Certificates Processing System: Demo & Q&A session for ...

Apr 26, 2025 0

Certificates Processing System: Demo & Q&A session for Industry stakeholders (H+...

Human medicines European public assessment report (EPAR): Omlyclo, omalizumab, Date of authorisation: 16/05/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 26, 2025 0

Human medicines European public assessment report (EPAR): Omlyclo, omalizumab, D...

Report - Industry stakeholders and EU network experts s...

Apr 26, 2025 0

Report - Industry stakeholders and EU network experts surveys on early engagemen...

Article 57 product data

Apr 26, 2025 0

Article 57 product data

Procurement

Apr 26, 2025 0

Procurement

Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 53, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 26, 2025 0

Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Da...

Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, Date of authorisation: 05/01/2024, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 26, 2025 0

Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, ...

CHMP opinions on consultation procedures

CHMP opinions on consultation procedures

Apr 26, 2025 0

CHMP opinions on consultation procedures

EU Implementation Guide (IG) on veterinary medicines pr...

Apr 26, 2025 0

EU Implementation Guide (IG) on veterinary medicines product data in the Union P...

Human medicines European public assessment report (EPAR): Wainzua, eplontersen, Date of authorisation: 06/03/2025, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 26, 2025 0

Human medicines European public assessment report (EPAR): Wainzua, eplontersen, ...

Human medicines European public assessment report (EPAR): Enjaymo, sutimlimab, Date of authorisation: 15/11/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 25, 2025 0

Human medicines European public assessment report (EPAR): Enjaymo, sutimlimab, D...

Human medicines European public assessment report (EPAR): Piasky, Crovalimab, Date of authorisation: 22/08/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 25, 2025 0

Human medicines European public assessment report (EPAR): Piasky, Crovalimab, Da...

Human medicines European public assessment report (EPAR): Alunbrig, brigatinib, Date of authorisation: 22/11/2018, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 25, 2025 0

Human medicines European public assessment report (EPAR): Alunbrig, brigatinib, ...

Human medicines European public assessment report (EPAR): Pemetrexed Pfizer (previously Pemetrexed Hospira), pemetrexed, Date of authorisation: 19/11/2015, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 25, 2025 0

Human medicines European public assessment report (EPAR): Pemetrexed Pfizer (pre...

Human medicines European public assessment report (EPAR): Steqeyma, ustekinumab, Date of authorisation: 22/08/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 25, 2025 0

Human medicines European public assessment report (EPAR): Steqeyma, ustekinumab,...

Human medicines European public assessment report (EPAR): Osenvelt, denosumab, Date of authorisation: 14/02/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 25, 2025 0

Human medicines European public assessment report (EPAR): Osenvelt, denosumab, D...

Human medicines European public assessment report (EPAR): Azacitidine Mylan, azacitidine, Date of authorisation: 27/03/2020, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 25, 2025 0

Human medicines European public assessment report (EPAR): Azacitidine Mylan, aza...

Human medicines European public assessment report (EPAR): Elocta, efmoroctocog alfa, Date of authorisation: 18/11/2015, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 25, 2025 0

Human medicines European public assessment report (EPAR): Elocta, efmoroctocog a...

Human medicines European public assessment report (EPAR): RotaTeq, rotavirus vaccine, live, Date of authorisation: 26/06/2006, Revision: 38, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 25, 2025 0

Human medicines European public assessment report (EPAR): RotaTeq, rotavirus vac...

New treatment against Duchenne muscular dystrophy

New treatment against Duchenne muscular dystrophy

Apr 25, 2025 0

New treatment against Duchenne muscular dystrophy

First treatment against severe thyroid eye disease

First treatment against severe thyroid eye disease

Apr 25, 2025 0

First treatment against severe thyroid eye disease

Human medicines European public assessment report (EPAR): Junod, denosumab, Status: Opinion

Human medicines European public assessment report (EPAR...

Apr 25, 2025 0

Human medicines European public assessment report (EPAR): Junod, denosumab, Stat...

Human medicines European public assessment report (EPAR): Sephience, sepiapterin, Status: Opinion

Human medicines European public assessment report (EPAR...

Apr 25, 2025 0

Human medicines European public assessment report (EPAR): Sephience, sepiapterin...

Human medicines European public assessment report (EPAR): Zadenvi, denosumab, Status: Opinion

Human medicines European public assessment report (EPAR...

Apr 25, 2025 0

Human medicines European public assessment report (EPAR): Zadenvi, denosumab, St...

1
2
3

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.